Pfizer exits ViiV Healthcare in $1.9B deal, Shionogi doubles stake to 21.7%, while GSK retains majority, advancing long-acting HIV treatments and prevention.
Novartis announced today that the FDA has granted Breakthrough Therapy designation to ianalumab for Sjogren’s disease, strengthening its path toward becoming the first targeted treatment for this autoimmune condition.
Illumina, Inc. has announced the launch of the Illumina Billion Cell Atlas, a large-scale genomic dataset intended to strengthen the scientific foundation of drug discovery and biomedical research. The announcement was made from San Diego on Thurs...
Venus Remedies has received regulatory approval in Indonesia for ceftazidime+avibactam, enabling the country’s first generic launch and marking the company’s entry into the anti-infective segment in the key ASEAN market.
Bristol Myers Squibb today reported positive Phase 3 results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data come from the Phase 3 SCOUT-HCM trial, the first study of a cardiac myosin inhibitor...
Novartis to build its fourth US radioligand therapy facility in Florida, boosting RLT supply, ensuring timely cancer treatment, and expanding its $23 billion US investment.
PharmNXT Biotech expands globally after acquiring Ireland’s DTR, adding GMP modular tubing tech to boost bioprocess efficiency, safety, and exports from India to Europe and Asia.
Panacea Biotec shares rise over 9% after completing Phase III enrollment for its dengue vaccine DengiALL, a potential first indigenous single-shot dengue vaccine in India.
Dr. Lal PathLabs Limited today announced the launch of the Sovaaka Diagnostic Experience Centre in Gurugram, marking a major step in the evolution of preventive healthcare in India. The launch was graced by Haryana Chief Minister Nayab Singh...
Torrent Pharma approves Rs 12,500 crore NCD issue to boost liquidity, fund acquisitions and capex, while maintaining strong balance sheet, low leverage, and long-term growth focus.